Author(s)

Suzannah M. Schmidt, Melissa J. Karau, Jayawant N. Mandrekar, James M. Steckelberg, Robin Patel

Department of Health Sciences Research Mayo Clinic, Division of Biomedical Statistics and Informatics, Rochester, US.
Department of Laboratory Medicine and Pathology, Division of Clinical Microbiology, Rochester, US.
Department of Medicine, Division of Infectious Diseases, Rochester, US.

We determined whether telavancin is as active in experimental immunocompetent murine pneumococcal pneumonia as is vancomycin or ceftriaxone. Experimental murine pneumonia was established by intratracheal administration of Streptococcus pneumoniae. Four groups of animals were studied, untreated and treated with vancomycin (110 mg/kg, bid, SQ), telavancin (40 mg/kg, bid, SQ), or ceftriaxone (50 mg/kg, bid, SQ) for 2 days. The untreated animals had a mean of 6.54 ± 0.82 log₁₀ cfu/g lung. The vancomycin-, telavancin-, and ceftriaxone-treated animals had means of 2.01 ± 0.02, 2.00 ± 0.00, and 2.00 ± 0.01 log₁₀ cfu/g lung, respectively (p-values < 0.0001 for each treatment group versus the untreated group). In the model studied, telavancin was as active as vancomycin and ceftriaxone in treating experimental pneumococcal pneumonia in mice.

Telavancin; Murine; Pneumonia

S. Schmidt, M. Karau, J. Mandrekar, J. Steckelberg and R. Patel, "Telavancin in Experimental Murine Pneumococcal Pneumonia," Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol. 1 No. 2, 2012, pp. 15-19. doi: 10.4236/jibtva.2012.12003.